Given this, in the present study, we recruited CTD patients with concurrent pSS, SSc, or PM/DM to quantify the serum levels of MUC5AC and MUC5B proteins and to compare the differences in expression among individuals with CTD, healthy controls, and individuals with CTD and concurrent ILD. This evidence concerns the gene MUC5B and dermatomyositis.